Early assessment of medical technologies to inform product development and market access

[1]  Maarten Joost IJzerman,et al.  A Comparison of Analytic Hierarchy Process and Conjoint Analysis Methods in Assessing Treatment Alternatives for Stroke Rehabilitation , 2012, The Patient - Patient-Centered Outcomes Research.

[2]  Johnathan Mun,et al.  Real options analysis : tools and techniques for valuing strategic investments and decisions , 2012 .

[3]  D. Spiegelhalter,et al.  Incorporation of uncertainty in health economic modelling studies , 2012, PharmacoEconomics.

[4]  D. Mortimer.  Modelling Downstream Effects in the Presence of Technological Change , 2012, PharmacoEconomics.

[5]  M. Sculpher,et al.  Using Value of Information Analysis to Prioritise Health Research , 2012, PharmacoEconomics.

[6]  J. Louviere,et al.  Conducting Discrete Choice Experiments to Inform Healthcare Decision Making , 2012, PharmacoEconomics.

[7]  Maarten J. IJzerman,et al.  Assessment of the added value of the Twente Photoacoustic Mammoscope in breast cancer diagnosis , 2011, Medical devices.

[8]  Bonny Parkinson,et al.  Integrating Health Economics Into the Product Development Cycle , 2011, Medical decision making : an international journal of the Society for Medical Decision Making.

[9]  Theo Stijnen,et al.  The Combined Analysis of Uncertainty and Patient Heterogeneity in Medical Decision Models , 2011, Medical decision making : an international journal of the Society for Medical Decision Making.

[10]  D. Exner,et al.  Combining Shock Reduction Strategies to Enhance ICD Therapy: A Role for Computer Modeling , 2011, Journal of cardiovascular electrophysiology.

[11]  Sylvie Chevret,et al.  Bayesian statistical method was underused despite its advantages in the assessment of implantable medical devices. , 2011, Journal of clinical epidemiology.

[12]  J. Gil,et al.  A stated preference analysis comparing the Analytical Hierarchy Process versus Choice Experiments , 2011 .

[13]  F. Johnson,et al.  How does cost matter in health-care discrete-choice experiments? , 2011, Health economics.

[14]  Maarten J. IJzerman,et al.  Patient Preferences for Next Generation Neural Prostheses to Restore Bladder Function , 2010, Spinal Cord.

[15]  Jason I Reminick,et al.  Funding of US Biomedical Research , 2011 .

[16]  J. Stockman.  Funding of US Biomedical Research, 2003-2008 , 2011 .

[17]  I. Schiller-Frühwirth,et al.  MO4 USING AHP WEIGHTS TO FILL MISSING GAPS IN MARKOV DECISION MODELS , 2011 .

[18]  J. D. de Bono,et al.  RETRACTED: Horizon scanning for novel therapeutics for the treatment of prostate cancer , 2010, Expert opinion on investigational drugs.

[19]  A. Attema,et al.  Investment in antiviral drugs: a real options approach. , 2010, Health economics.

[20]  Uwe Siebert,et al.  The efficiency frontier approach to economic evaluation of health-care interventions. , 2010, Health economics.

[21]  Adrian Towse,et al.  Value based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong? , 2010, British journal of clinical pharmacology.

[22]  N. Holford,et al.  Clinical Trial Simulation: A Review , 2010, Clinical pharmacology and therapeutics.

[23]  Richard Lilford,et al.  Early-stage valuation of medical devices: the role of developmental uncertainty. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[24]  Karl Claxton,et al.  Eliciting distributions to populate decision analytic models. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[25]  S. Aronoff,et al.  A valuation of infusion therapy to preserve islet function in type 1 diabetes. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[26]  K. Facey,et al.  Patients' perspectives in health technology assessment: A route to robust evidence and fair deliberation , 2010, International Journal of Technology Assessment in Health Care.

[27]  Lili M. Portilla,et al.  Reaping the Benefits of Biomedical Research: Partnerships Required , 2010, Science Translational Medicine.

[28]  J. Bridges,et al.  What outcomes should US policy makers compare in comparative effectiveness research? , 2010, Expert review of pharmacoeconomics & outcomes research.

[29]  Mark J Sculpher,et al.  Using the incremental net benefit framework for quantitative benefit-risk analysis in regulatory decision-making--a case study of alosetron in irritable bowel syndrome. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[30]  Scott C. Molitor,et al.  Biodesign: The Process of Innovating Medical Technologies , 2010 .

[31]  Sindhu R Johnson,et al.  Methods to elicit beliefs for Bayesian priors: a systematic review. , 2010, Journal of clinical epidemiology.

[32]  Sindhu R Johnson,et al.  A valid and reliable belief elicitation method for Bayesian priors. , 2010, Journal of clinical epidemiology.

[33]  G. Lindberg,et al.  EVITA: a tool for the early EValuation of pharmaceutical Innovations with regard to Therapeutic Advantage , 2010, BMC clinical pharmacology.

[34]  R. Majdzadeh,et al.  Systematic review of methods for evaluating healthcare research economic impact , 2010, Health research policy and systems.

[35]  Hassan Masum,et al.  Five promising methods for health foresight , 2010 .

[36]  Patrice Talaga,et al.  Open innovation: share or die... , 2009, Drug discovery today.

[37]  Alan L. Porter,et al.  A systematic technology forecasting approach for New and Emerging Science and Technology: Case study of nano-enhanced biosensors , 2009, 2009 Atlanta Conference on Science and Innovation Policy.

[38]  Valesca P Retèl,et al.  Review on early technology assessments of nanotechnologies in oncology , 2009, Molecular oncology.

[39]  M. Ijzerman,et al.  PP1 - A systematic review of the analytic hierarchy process in health care decision making , 2009 .

[40]  E. Torri,et al.  The timing of adoption of positron emission tomography: a real options approach , 2009, Health care management science.

[41]  Karl Claxton,et al.  Characterizing structural uncertainty in decision analytic models: a review and application of methods. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[42]  N. Cohen,et al.  Open innovation networks between academia and industry: an imperative for breakthrough therapies , 2009, Nature Medicine.

[43]  Vladan Babovic,et al.  Reducing Risk Through Real Options in Systems Design: The Case of Architecting a Maritime Domain Protection System , 2009, Risk analysis : an official publication of the Society for Risk Analysis.

[44]  J. John,et al.  Public Health Policy Decisions on Medical Innovations: What Role Can Early Economic Evaluation Play? , 2009, Health policy.

[45]  L. Steuten,et al.  Analysing uncertainty around costs of innovative medical technologies: the case of fibrin sealant (QUIXIL) for total knee replacement. , 2009, Health policy.

[46]  Thomas M. Krummel,et al.  'Biodesign: The Process of Innovating Medical Technologies , 2009 .

[47]  A Boltong,et al.  A review of health impact assessment frameworks. , 2008, Public health.

[48]  Susanne Hartz,et al.  Contribution of economic evaluation to decision making in early phases of product development: A methodological and empirical review , 2008, International Journal of Technology Assessment in Health Care.

[49]  Laura Vallejo-Torres,et al.  Integrating health economics modeling in the product development cycle of medical devices: A Bayesian approach , 2008, International Journal of Technology Assessment in Health Care.

[50]  Claudia Wild,et al.  Emerging health technologies: informing and supporting health policy early. , 2008, Health policy.

[51]  Maarten J. IJzerman,et al.  Decision for reconstructive interventions of the upper limb in individuals with tetraplegia: the effect of treatment characteristics , 2008, Spinal Cord.

[52]  M Elisabeth Paté-Cornell,et al.  Early technology assessment of new medical devices , 2008, International Journal of Technology Assessment in Health Care.

[53]  Karl Claxton,et al.  The Value of Implementation and the Value of Information: Combined and Uneven Development , 2008, Medical decision making : an international journal of the Society for Medical Decision Making.

[54]  Mandy Ryan,et al.  Using discrete choice experiments to value health and health care , 2008 .

[55]  Shelby D. Reed,et al.  Economic Implications of Potential Changes to Regulatory and Reimbursement Policies for Medical Devices , 2007, Journal of General Internal Medicine.

[56]  Peter Wood,et al.  Cost‐effectiveness analysis at the development phase of a potential health technology: examples based on tissue engineering of bladder and urethra , 2007, Journal of tissue engineering and regenerative medicine.

[57]  Richard J. Lilford,et al.  Investing in new medical technologies: A decision framework , 2007 .

[58]  Kieran Murphy,et al.  Effective early warning systems for new and emerging health technologies: Developing an evaluation framework and an assessment of current systems , 2007, International Journal of Technology Assessment in Health Care.

[59]  Peter C. Smith,et al.  A Real Options Approach to Watchful Waiting: Theory and an Illustration , 2007, Medical decision making : an international journal of the Society for Medical Decision Making.

[60]  I. Chalmers.  Biomedical research: Are we getting value for money? , 2006 .

[61]  S. Hanney,et al.  Building health research systems to achieve better health , 2006, Health research policy and systems.

[62]  Karl Claxton,et al.  An Iterative Bayesian Approach to Health Technology Assessment: Application to a Policy of Preoperative Optimization for Patients Undergoing Major Elective Surgery , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.

[63]  H. Ross,et al.  The effect of imposing a higher, uniform tobacco tax in Vietnam , 2006, Health research policy and systems.

[64]  C. Herstatt,et al.  Users' Contributions to Radical Innovation: Evidence from Four Cases in the Field of Medical Equipment Technology , 2006 .

[65]  H. Chesbrough,et al.  Beyond High Tech: Early Adopters of Open Innovation in Other Industries , 2006 .

[66]  Ali H. Hassan,et al.  Application of real options analysis for pharmaceutical R&D project valuation—Empirical results from a survey , 2006 .

[67]  Karla Douw,et al.  Selection of new health technologies for assessment aimed at informing decision making: A survey among horizon scanning systems , 2006, International Journal of Technology Assessment in Health Care.

[68]  Maarten J. IJzerman,et al.  A preliminary economic evaluation of percutaneous neuromuscular electrical stimulation in the treatment of hemiplegic shoulder pain , 2006, Disability and rehabilitation.

[69]  Wonjoon Kim,et al.  Demand forecasting for multigenerational products combining discrete choice and dynamics of diffusion under technological trajectories , 2005 .

[70]  Karl Claxton,et al.  Establishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty--when is there sufficient evidence? , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[71]  A. O'Hagan,et al.  Statistical Methods for Eliciting Probability Distributions , 2005 .

[72]  A. Brennan,et al.  Should patients have a greater role in valuing health states? , 2005, Applied health economics and health policy.

[73]  F. De Ridder,et al.  Predicting the outcome of phase III trials using phase II data: a case study of clinical trial simulation in late stage drug development. , 2005, Basic & clinical pharmacology & toxicology.

[74]  Robert Phaal,et al.  Technology roadmapping—A planning framework for evolution and revolution , 2004 .

[75]  Joseph P. Martino,et al.  A review of selected recent advances in technological forecasting , 2003 .

[76]  Q. B. Chung,et al.  Using the analytic hierarchy process as a clinical engineering tool to facilitate an iterative, multidisciplinary, microeconomic health technology assessment , 2003, Comput. Oper. Res..

[77]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[78]  Hui C. Kimko,et al.  Simulation for Designing Clinical Trials : A Pharmacokinetic-Pharmacodynamic Modeling Perspective , 2002 .

[79]  Costas D. Maranas,et al.  Real Options Based Analysis of Optimal Pharmaceutical Research and Development Portfolios , 2002 .

[80]  M. Drummond,et al.  A rational framework for decision making by the National Institute For Clinical Excellence (NICE) , 2002, The Lancet.

[81]  D McDaid,et al.  Wrong SIGN, NICE mess: is national guidance distorting allocation of resources? , 2001, BMJ : British Medical Journal.

[82]  H. Moses,et al.  Academic relationships with industry: a new model for biomedical research. , 2001, JAMA.

[83]  G. Rakhorst,et al.  Medical Technology Assessment: The use of the Analytic Hierarchy process as a Tool for Multidisciplinary Evaluation of Medical Devices , 2000, The International journal of artificial organs.

[84]  I Chalmers,et al.  Evaluating “payback” on biomedical research , 2000, BMJ : British Medical Journal.

[85]  Robert Cottrell,et al.  Evaluating “payback” on biomedical research from papers cited in clinical guidelines: applied bibliometric study , 2000, BMJ : British Medical Journal.

[86]  R. Mulye.  An empirical comparison of three variants of the AHP and two variants of conjoint analysis , 1998 .

[87]  P. Carlsson,et al.  Scanning the Horizon for Emerging Health Technologies: Conclusions from a European Workshop , 1998, International Journal of Technology Assessment in Health Care.

[88]  Anthony O'Hagan,et al.  Eliciting expert beliefs in substantial practical applications , 1998 .

[89]  Brian Shaw,et al.  Innovation and new product development in the UK medical equipment industry , 1998 .

[90]  A. Rip,et al.  The past and future of constructive technology assessment , 1997 .

[91]  M. Drummond,et al.  The Iterative Use of Economic Evaluation as Part of the Process of Health Technology Assessment , 1997, Journal of health services research & policy.

[92]  James E. Smith,et al.  Valuing Risky Projects: Option Pricing Theory and Decision Analysis , 1995 .

[93]  N. Rosenberg,et al.  The dynamics of technological change in medicine. , 1994, Health affairs.

[94]  Thomas L. Saaty,et al.  The analytic hierarchy process : planning, priority setting, resource allocation , 1980 .